A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate*) for folliculogenesis in routine in vitro fertilization patients
|
|
- Logan Booker
- 5 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY Copyright" 1991 The American Fertility Society Vol. 56, No. 3, September 1991 Printed on acid-free paper in U.S.A. A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate*) for folliculogenesis in routine in vitro fertilization patients David W. Polson, M.D.t Vivien MacLachlan, B.Sc. Jennifer A. Krapez, B.Sc. Carl Wood, M.B. David L. Healy, Ph.D. Monash IVF Programme, Infertility Medical Centre, Epworth Hospita~ Richmond, Victoria, Australia Study Objective: To determine if gonadotropin-releasing hormone agonist (GnRH-a) and gonadotropin therapy could improve folliculogenesis and pregnancy rates (PRs) in women with a previously satisfactory response to clomiphene citrate and human menopausal gonadotropin (hmg). Design: Randomized prospective study. Setting: Assisted reproduction clinic. Patients: One hundred fifty-seven women were randomized to receive either hmg alone or the GnRH-a buserelin acetate 600 p.gfd or buserelin acetate 1,200 p.gfd plus hmg. Results: Compared with hmg alone, pretreatment with buserelin acetate significantly increased the PR per cycle started by preventing a premature luteinizing hormone rise and thereby reducing the number of abandoned cycles. There was, however, no difference between the number of follicles aspirated, oocytes obtained, or fertilization rates between groups. Furthermore, agonist therapy significantly increased both the dose of hmg required and the duration of stimulation. Conclusion: The routine use of GnRH -a in in vitro fertilization programs must be questioned. Fertil Steril 56:509, 1991 The use of long-acting gonadotropin-releasing hormone agonists (GnRH-a) has been recently reported in women undergoing controlled hyperstimulation for in vitro fertilization (IVF) programs. 1-5 Reports suggest improvements in follicular recruitment, oocyte number and quality, fertilization rates, number of embryos transferred and pregnancy rates (PRs). In addition, there is a reported reduction in the number of abandoned cycles because of prevention of an inappropriate rise in the serum luteinizing hormone (LH) or progesterone (P) concentration. 6 This has led to the suggestion that GnRH -a be used in all IVF-gamete intrafallopian transfer (GIFT) treatment cycles. 4 5 Received December 27, 1989; revised and accepted May 9, * Buserelin acetate, Suprefact; Hoechst, Melbourne, Victoria, Australia. t Reprint requests: David Polson, M.D., Department of Obstetrics and Gynaecology, Withington Hospital, Nell Lane, West Didsbury, Manchester M20 8LR, United Kingdom. Vol. 56, No. 3, September 1991 Unfortunately, these conclusions have been drawn from poorly controlled and nonrandomized studies with patients being specifically allocated to GnRHa therapy Most of these reports do confirm improved folliculogenesis in women who fail to respond satisfactorily to treatment with clomiphene citrate (CC) and human menopausal gonadotropin (hmg). 7-9 There is, however, little evidence for a similar improvement in women who respond satisfactorily to CC-hMG. Furthermore, there have been no dose-response studies to determine the dose of agonist required. We have therefore performed a randomized study to: (1) compare folliculogenesis and pregnancy outcome in women with a previously normal response to CC-hMG after randomization to receive either hmg alone, buserelin acetate 600 f.l.g/d plus hmg, or buserelin acetate 1,200 f.l.g/d plus hmg; and (2) determine any differences in patient response to either of these two doses of buserelin acetate. Polson et al. GnRH-a in routine IVF patients 509 I
2 Patients MATERIALS AND METHODS One hundred fifty-seven apparently endocrinenormal IVF patients with tubal (n = 76) or idiopathic (n = 81) infertility entered the study between September 1988 and February Couples with idiopathic infertility had failed to conceive after at least 18 months regular unprotected intercourse despite ovulatory cycles, a normal semen analysis as defined by the World Health Organization classification and a normal pelvic appearance at laparoscopy. All patients were.::;;37 years old and had a previously satisfactory response after our standard regimen of CC (Clomid; Merrell Dow, Sydney, New South Wales, Australia) 100 mg days 3 to 7 and hmg (Pergonal; Serono, Melbourne, Victoria, Australia) 150 IU from day 4. 10' 11 This was defined by a serum estradiol (E2) concentration > 3,600 pmol/l, more than three follicles > 17 mm in diameter noted on ultrasound (US) before the administration of human chorionic gonadotrophin (hcg) and the recovery of more than one oocyte. Patients were randomized by simple randomization using a single sequence of random numbers. The randomization was centralized but was not s~ratified, and blocking was not used. The sample s1ze based on 80% power and a level of significance of 5% was 150 patients. Patients were randomized to receive hmg or intranasal buserelin acetate (Suprefact; Hoechst, Melbourne, Victoria, Australia) 600 J.Lg/d (buserelin acetate 600) or 1,200 J.Lg/d (buserelin acetate 1,200) plus hmg. Fifty women received hmg (26 with tubal infertility; 24 with idiopathic infertility), 51 received buserelin acetate 600 (25 tubal, 26 idiopathic), and 56 received buserelin acetate 1,200 (25 tubal, 31 idiopathic). Fifty-six cycles were initiated in each of the hmg and buserelin acetate 600 groups and 64 cycles in the buserelin acetate 1,200 group. The mean age (range) in each group was similar; 31.3 years (23 to 36), 32.5 years (26 to 37), and 32.7 years (26 to 37) respectively. Methods Women assigned to treatment with buserelin acetate started on day 3 of the cycle after measurements of serum E2, P, and LH concentrations. 11,12 One or two doses of buserelin acetate 150 J.Lg were administered intranasally at regular intervals four time~ ~er d~y. For the buserelin acetate 600 group, admtmstratwn was to one nostril only (4 X 150 J.Lg) and for the buserelin acetate 1,200 group to both nostrils (4 X 300 J.Lg). Initially, weekly blood tests were taken to assess pituitary and ovarian suppression. When the serum E2 concentrations were <180 pmol/l on two consecutive daily blood samples, treatment with hmg was started. Women assigned to receive hmg alone commenced on day 3 of the cycle. The hmg alone and buserelin acetate-hmg groups received the same initial dosage of 300 IU, 300 IU, 150 IU, and 150 IU hmg for the 1st 4 days. On the 4th day of treatment, and daily thereafter, serum E2, LH, and P concentrations were measured. The dosage of hmg was adjusted according to the rise in serum E2 concentration and follicular developmen~ as noted by vaginal pelvic ultrasonography, as prevwusly describedy Cycles were abandoned if there was an unsatisfactory follicular response and low serum E2 concentrations, despite a high daily dose of hmg {up to 675 IU). Human chorionic gonadotropin, 5,000 IU, was administered when there were at least three follicles > 17 mm in diameter and the serum E2 concentration was >3,600 pmoljl. Buserelin acetate was then discontinued. Depending on the indication for infertility, either gamete intrafallopian transfer (GIFT), pronuclear stage transfer, or an IVF procedure was performed 36 hours later, as previously described. 10,13 For IVF, embryo transfer (ET) took place 48 to 72 hours after US-guided vaginal oocyte recovery.14 The luteal phase was supported in all three groups. For the 1st 2 months of the study, 1,000 IU ofhcg was administered on days 3, 6, and 9, but after two cases of moderate hyperstimulation requiring hospitalization, this dose was reduced to 500 IU on days 6 and 9. Serum concentrations of hcg, E2, and P were measured 14 days after oocyte recovery and any pregnancies confirmed by ultrasonography 14 to 21 days later. Only clinical pregnancies were recorded (i.e., presence of gestational sac with or without fetal complex, or ectopic pregnancy). If an LH surge occurred in the presence of three or more follicles and satisfactory serum E2 concentrations (>3,600 pmol/l), oocyte recovery was performed 36 hours from the onset of the surge. If there was an LH surge without these criteria being met, the cycle was abandoned. Statistical Analysis Statistical analysis was performed using Wilcoxon's rank sum test, Fisher's exact probability test d 2 ' an the X test as nonparametric methods to ex- 510 Polson et al. GnRH-a in routine IVF patients Fertility and Sterility
3 amine relationships between groups. Probability value < 0.05 was considered significant. Down Regulation Phase RESULTS There was a similar time taken in both the buserelin acetate 600 and buserelin acetate 1,200 groups to achieve suppression of serum E 2 concentrations (buserelin acetate 600, 22 days [6 to 41]; buserelin acetate 1,200, 23 days [7 to 30]; median [range]). Serum LH and P concentrations were usually low (i.e., <10 IU/L and <3 nmol/l, respectively) within 2 weeks of commencing buserelin acetate, with the delay in E 2 suppression because of ovarian stimulation with the increase in endogenous gonadotropin release on commencing agonist therapy. Thirty-five of 56 buserelin acetate 600 cycles (62%) and 45 of 64 buserelin acetate 1,200 cycles (70%) showed an initial rise in serum E 2 concentrations to above 400 pmol/l. In both groups, the elevation was similar (buserelin acetate 600 1,325 pmol/l [425 to 6,050], buserelin acetate 1,200 1,465 pmol/l [410 to 5,800]; median [range]). This stimulation was not influenced by baseline serum LH or E 2 concentrations, which were similar for both groups. On the initial US examination, 61% of these women had one or more follicular cysts > 20 mm in diameter, which were presumably unruptured follicular cysts associated with ovarian stimulation because in 44 of these 49 cases there had been a rise in serum E 2 concentration. These cysts did not interfere with follicular growth during stimulation with hmg and were aspirated at the time of oocyte recovery. Stimulation Phase Table 1 summarises the number of completed cycles in each group and the indication for abandoning treatment. Women receiving hmg alone were significantly more likely to be discharged, usually because of a premature LH surge. Only 7 of the 120 (6%) buserelin acetate cycles were abandoned, and none were because of an LH surge. In four patients there was poor follicular development, two had elevated serum progesterone concentrations, and one woman stopped sniffing for social reasons. Both doses of buserelin acetate were associated with a significant increase in the duration and dosage of hmg required when compared with the hmg only group. Within the buserelin acetate group, women Table 1 Treatment Groups No. of women No. of cycles No. of abandoned cycles Serum E 2 < 1,600 pmol/l Premature LH surge Serum P > 7 nmol/l Self-discharge Buserelin acetate Buserelin acetate 1, HMG " 2 13 Buserelin acetate 600 and buserelin acetate 1,200 groups are significantly different from hmg group (P < 0.01). receiving 600 J.tg/d had a significantly shorter stimulation time and required less hmg than those receiving 1,200 J.tg/d. In neither group was there any correlation between the time taken to achieve suppression of serum E 2 concentrations and the subsequent stimulation phase with hmg, i.e., a long suppression period was not associated with the need for higher doses of hmg. Furthermore, follicular stimulation on commencing buserelin acetate did not influence the response to hmg therapy. The peak serum E 2 concentration before administration of hcg before oocyte recovery was significantly lower in both buserelin acetate groups compared with the hmg group (see Table 2). There was no relationship between the low E 2 concentration and the duration or dose of buserelin acetate therapy. Oocyte Recovery and Fertilization Rates A similar median number of follicles was aspirated in each group-9, 9, and 8 in the buserelin acetate 600, buserelin acetate 1,200, and hmg groups, respectively, with a similar range of between 2 and 29 follicles. There was also a similar median number of oocytes obtained-5 in the buserelin acetate 600 group (range 0 to 23), 6 in the buserelin acetate 1,200 group (O to 13), and 5 in the hmg group (O to 21). There was no significant difference in the fertilization rates between any of the groups (56.5%, 63.4%, and 65.1% for buserelin acetate 600, buserelin acetate 1,200, and hmg, respectively). Therefore, in this randomized study buserelin acetate did not improve the number of oocytes obtained compared with hmg alone, nor were the fertilization rates higher, suggesting similar oocyte quality. It was interesting to note that similar follicle and oocyte numbers were obtained from buserelin acetate cycles, despite a significantly lower peak serum E 2 concentration. Vol. 56, No.3, September 1991 Polson et al. GnRH-a in routine IVF patients 511
4 Table 2 Characteristics of the Three Groups Buserelin acetate 600 (n =52) Buserelin acetate 1,200 (n = 61) HMG (n = 41) Duration of hmg (d) Total dose of hmg (no. of ampules 75 IU FSH/75 IU LH) Peak serum E 2 concentration (pmol/l) (16 to 66)c 5,505 (355 to 13,210) 11a 30 (13 to 77)a 19 (11 to 35)b 5,870 (3,260 to 13,210) 7,340 (3,255 to 13,210)d a Buserelin acetate 600 significantly different from buserelin acetate 1,200 group (P < 0.05). b Buserelin acetate 600 and buserelin acetate 1,200 groups significantly different from hmg group (P < 0.001). c Values are medians with ranges in parentheses. d Buserelin acetate 600 and buserelin acetate 1,200 groups significantly different from hmg group (P < 0.01). There was a positive correlation between the E 2 level before oocyte recovery and the number of oocytes obtained for both groups: buserelin acetate (r = 0.32, P < 0.01; Spearman rank correlation) and hmg only (r = 0.38, P < 0.05). Outcome of Therapy Of the 52 cycles in women receiving buserelin acetate 600 resulting in oocyte recovery, there were 9 cycles without oocyte or ET because of a failure of fertilization, and in one cycle no oocytes were obtained. There were 31 cycles of IVF-ET, 10 GIFT, and 1 pronuclear stage transfer cycle. For women receiving buserelin acetate 1,200, no oocytes were obtained in 3 cycles and an additional 7 had no ET because of either a failure of fertilization (5 cycles) or abnormal embryonic development (2 cycles). This resulted in 51 completed cycles (35 IVF-ET, 14 GIFT, and 2 pronuclear stage transfer). In the hmg group, 5 of the 41 cycles did not proceed to oocyte/ ET because of no oocytes being obtained (3 cycles) or a failure of fertilization (2 cycles), leading to 26 IVF-ET and 10 GIFT cycles. Because GIFT and IVF have different PRs, which are dependent on the number of oocytes and embryos transferred, the pregnancy outcome for each group is classified accordingly (see Table 3). The pronuclear stage transfer cycles are included with the IVF results. Only clinical pregnancies are reported as defined earlier. For IVF-ET and pronuclear stage transfer cycles, the buserelin acetate 600 and buserelin acetate 1,200 groups had higher rates of 3 to 4 ETs than the hmg group (75% and 78% versus 58%). Despite this, there was a similar PR per ET for all groups. For GIFT cycles, there were no pregnancies in women receiving hmg only. This was significantly lower (P < 0.05; Fisher's test) than the PR in the buserelin acetate 1,200 group, although the numbers in each group were small. Considering both IVF and GIFT cycles and the various stimulation regimens, there was no difference in the overall clinical PR per transfer between the groups. However, if clinical pregnancies per treatment cycle commenced were compared, hmg stimulation achieved a significantly lower PR than women receiving buserelin acetate 1,200 (P < 0.05; Fisher's test). There was no difference in the PRs between the buserelin acetate 600 and buserelin acetate 1,200 groups. Sixteen of the 20 pregnancies with buserelin acetate had a peak serum E 2 concentration between 4,400 and 9,250 pmol/l with 1 < 3,600 pmol/l and 3 > 9,250 pmol/l. We have previously demonstrated that E 2 concentrations between 5,000 and 10,000 pmol/l in CC-hMG stimulation cycles are optimal for conception. 15 These similar results with buserelin acetate support the suggestion that the peak serum E 2 concentrations are important for the establishment and maintenance of a pregnancy. Table 3 Clinical PRs in Women Receiving Buserelin Acetate 600, Buserelin Acetate 1,200, or HMG Buserelin Buserelin acetate 600 acetate 1,200 HMG IVF 1 to 2 ET 0/8 1/8 1/11 3 to 4 ET 6/24 4/29 2/15 Total 6/32 5/37 3/26 (18.8)a (13.5) (11.5) GIFT 1 to 3 oocytes 0/2 0/0 0/2 4 to 6 oocytes 3/8 6/14 0/8 Total 3/10 6/14 0/10 (30) (42.8) (O)b IVF and GIFT clinical 9/42 11/51 3/36 PR/transfer (21.4) (21.6) (8.3) Clinical PR/cycle started 9/56 11/64 3/56 (16.1) (17.2) (5.4)b a Values in parentheses are percents. b Buserelin acetate 1,200 significantly different from hmg-only group (P < 0.05). 512 Polson et al. GnRH-a in routine IVF patients Fertility and Sterility
5 DISCUSSION Reports of improved follicular recruitment, oocyte quality, and PRs in women who fail to respond to CC-hMG stimulation by the use of GnRH-a have led some groups to suggest their routine use for all women undergoing ovarian stimulation for IVF-ET f GIFT. 4 5 Our results with buserelin acetate-hmg do confirm a higher PR per treatment cycle because of a significant reduction in the number of abandoned cycles rather than any improvement in folliculogenesis. Twenty-seven percent of the hmg cycles were abandoned. In all but two patients, this was because of an inappropriate LH surge at the time of a low follicle number and low serum E2 concentrations. No buserelin acetate cycles were canceled because of an LH surge, although two cycles were abandoned because of elevation of the serum P concentration. One of these cases was probably because of poor patient compliance and the second may have been related to the presence of a functional ovarian cyst (50 X 40mm) noted on her first US scan. Elevated serum P concentrations in the late follicular phase are associated with a poor IVF outcome, in contrast to a rise only in the follicular phase which does not influence PR Gonadotropin-releasing hormone agonists therapy clearly reduced the likelihood of a patient being discharged from treatment before oocyte recovery by prevention of an unwanted LH surge. Buserelin acetate ensured a higher percentage of patients proceeded to oocyte retrieval. We did not find buserelin acetate increased the number of oocytes obtained nor improved the quality of oocytes as suggested by their fertilization rate when compared with hmg alone. The same number of oocytes was obtained with a significantly lower serum E2 concentration. The reason for this is unclear but may reflect a direct action of buserelin acetate on follicle-stimulating hormone (FSH) action at the granulosa cell level or a reduction in FSH receptors on granulosa cells. It was not dependent on the duration of buserelin acetate therapy. However, serum E2 concentrations may be important for establishing pregnancy and Yamashita and associates15 have recently suggested serum E2 concentrations between 5,000 and 10,000 pmol/l were significantly more likely to result in pregnancy regardless of the number of embryos transferred. This may be because of improved endometrial receptivity, which has been suggested with GnRH-a therapy.18 The PR per ET was similar between the buserelin acetate and the hmg-only groups. Gamete intra- fallopian transfer treatment was more successful overall, although it remains unclear why there were no pregnancies in the hmg-only group. This may reflect a higher percentage of immature oocytes as previously reported with hmg stimulation19 or simply the relatively small numbers of patients in this study. The higher PR observed in the buserelin acetate group was at the expense of a significantly longer stimulation period and much higher hmg requirements. This may reflect the absence of endogenous gonadotropin release, although another theoretical consideration may be a reduction in growth hormone (GH) release from the pituitary. Recent results from in vitro studies have confirmed that GH has a facilitatory action on FSH-induced granulosa cell activity, acting either directly on granulosa cells20 or mediated through increased production of insulinlike growth factors In vivo work has also suggested that GH may play a role in folliculogenesis. 23 In addition to the significantly higher cost of hmg when used with buserelin acetate in this study, there is also the additional cost of the GnRH -a. We could find very little data on dose-response testing of GnRH-a in clinical IVF. This study shows that a dose of 600 f.lg/ d of buserelin acetate achieved satisfactory pituitary suppression and that higher doses are unnecessary. We would conclude that buserelin acetate-hmg appears to offer an advantage to hmg alone for IVF superovulation by the elimination of unwanted LH surges. Randomized trials of CC-hMG and buserelin acetate-hmg in endocrine-normal IVF patients undergoing their first or subsequent IVF cycle should now be considered. For GnRH -a to have a place in the routine management of IVF subjects, clinical advantages or improved ongoing PRs will need to be proven. For women in whom there is a premature LH surge or a failure of adequate folliculogenesis with CC-hMG, we would recommend the use ofbuserelin acetate 600 f.lg/ d to achieve ovarian suppression before hmg stimulation. Acknowledgments. The authors gratefully thank the clinical, secretarial, and laboratory staff of the Infertility Medical Centre for their assistance and Takanori Yamashita, M.D., for statistical advice. REFERENCES 1. Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS: Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 2:1284, 1984 Vol. 56, No.3, September 1991 Polson et al. GnRH-a in routine IVF patients 513
6 2. Serafini P, Stone B, Kerin J, Batzofin J, Quinn P, Marrs RP: An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog. Fertil Steril49:90, Frydman R, Parneix J, Belaisch-Allart JC, Fosman R, Hazout A, Testart J: LHRH agonists in IVF: different methods of utilization and comparison with previous ovulation stimulation treatments. Hum Reprod 3:559, Rutherford AJ, Suback-Sharpe RJ, Dawson KJ, Margara RA, Franks S, Winston RML: Improvement of in vitro fertilization after treatment with buserelin, an agonist of luteinising hormone releasing hormone. Br Med J 296:1765, Meldrum DR, Wisot A, Hamilton F, Gutlay AL, Kempton W, Huynh D: Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. Fertil Steril 51:455, Fleming R, Coutts JRT: Induction of multiple follicular growth in normally menstruating women with endogenous gonadotrophin suppression. Fertil Steril 45:226, Smitz J, Devroey P, Camus M, Khan I, Staessen C, van Waesberghe L, Wisanto A, van Steirteghem AC: Addition of buserelin to human menopausal gonadotrophins in patients with failed stimulations for IVF and GIFT. Hum Reprod 3: 35, Belaish-Allart J, Testart J, Frydman R: Utilization of GnRH agonists for poor responders in an IVF programme. Hum Reprod 4:33, MacLachlan V, Besanko M, O'Shea F, Wade H, Wood EC, Trounson A, Healy DL: A controlled study of luteinizing hormone releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization. N Eng! J Med 320:1233, TrounsonA, LeetonJ, WoodC, WebbJ, WoodJ: Pregnancies in humans by fertilization in vitro and embryo transfer in the controlled ovulatory cycle. Science 212:681, Okamoto S, Healy D, Howlett DT, Rogers PAW, Leeton JF, Trounson AO, Wood EC: An analysis of plasma estradiol concentrations during clomiphene citrate-human menopausal gonadotrophin stimulation in an in vitro fertilization-embryo transfer program. J Clin Endocrinol Metab 63:736, Trounson A, Calabresse R: Changes in plasma progesterone concentrations around the time of the luteinizing hormone surge in women superovulated for in vitro fertilization. J Clin Endocrinol Metab 59:1075, Leeton J, Rogers P, Caro C, Healy D, Yates C: A controlled study between the use of gamete intrafallopian transfer (GIFT) and in vitro fertilization and embryo transfer in the management of idiopathic and male infertility. Fertil Steril 48:605, Lenz S, Leeton J, Renou P: Transvaginal recovery of oocytes for in vitro fertilization using vaginal ultrasound. J In Vitro Fert Embryo Transfer 4:51, Yamashita T, Besanko M, MacLachlan V, Polson DW, Healy DL: Plasma estradiol profiles during clomiphene citrate-human menopausal gonadotrophin stimulation and pregnancy rates in in vitro fertilization-embryo transfer, pronuclear stage tubal transfer and gamete intrafallopian transfer. (Abstr. 62) Presented at the 8th Annual Meeting of the Fertility Society of Australia, Canberra, Australia, November 27 to 30, Published by the Fertility Society of Australia, in Proceedings of the Fertility Society of Australia, 1989, p Kerin JF, Warnes GM: Monitoring of ovarian response to stimulation in in vitro fertilization cycles. Clin Obstet Gynaecol 29:158, Sathanadan M, Warnes GM, Kirby CA, Petrucco OM, Matthews CD: Adjuvant leuprolide in normal, abnormal and poor responders to controlled ovarian hyperstimulation for IVF / GIFT. J Clin Endocrinol Metab 51:998, Testart J, Forman R, Belaisch-Allart J, Volante M, Hazout A, Strubb N, Frydman R: Embryo quality and uterine receptivity in in vitro fertilization cycles with or without agonists of gonadotrophin-releasing hormone. Hum Reprod 4:198, Laufer N, Tarlatzis BC, DeCherney AH, Masters JT, Haseltine FP, MacLusky N, Naftolin F: Asynchrony between human cumulus-corona cell complex and oocyte maturation after human menopausal gonadotropin treatment for in vitro fertilization. Fertil Steril 42:366, Jiu X-C, Kalmiju J, Hseuh AJW: Growth hormone enhances follicle stimulating hormone-induced differentiation of cultured rat granulosa cells. Endocrinology 118:1401, Davoren B, Hseuh AJW: Growth hormone increases ovarian levels of immunoreactive somatomedin-c/insulin-like growth factor-1 in vivo. Endocrinology 118:888, Adashi EY, Resnick CE, Hernandez ER, Svoboda ME, Van Wyk JJ: In vivo regulation of granulosa cell somatomedin C/insulin-like growth factor-1 receptors. Endocrinology 122: 1383, Homburg R, Eshel A, Abdalla HI, Jacobs HS: Growth hormone facilitates ovulation induction by gonadotrophins. Clin Endocrinol (Oxf) 29:113, Polson et al. GnRH-a in routine IVF patients Fertility and Sterility
Programming in vitro fertilization for a 5- or 3-day week
Ass~st.d.reproductive tec"no'ogy FERTILITY AND STERILITY Copyright I[J 1991 The American Fertility Society Printed on acid-free paper in U.S.A. Programming in vitro fertilization for a 5- or 3-day week
More informationProspective study of short and ultrashort regimens of gonadotropinreleasing hormone agonist in an in vitro fertilization program
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Prospective study of short and ultrashort regimens of gonadotropinreleasing hormone agonist in
More informationFixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol
Yamanashi Med. J. 14(3), 77 ~ 82, 1999 Original Article Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Tsuyoshi KASAI and Kazuhiko
More informationDepartment of Gynaecology and Reproductive Medicine, University Hospital, University of Western Ontario, London, Ontario, Canada
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationThe predictive value of idiopathic failure to fertilize on the first in vitro fertilization attempt*
FERTILITY AND STERILITY Copyright 1991 The American Fertility Society Printed on acid-free paper in U.S.A. The predictive value of idiopathic failure to fertilize on the first in vitro fertilization
More informationOvarian response in three consecutive in vitro fertilization cycles
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in
More informationProspective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program
FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U. s. A. Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in
More informationIn Vitro Fertilization and Embryo Transfer
Acta Medica et Biologica Vol. 41, No.4, 171-176, 1993 The Influence of Low Ovarian Response on the Results of In Vitro Fertilization and Embryo Transfer Hirofumi HIRASAWA Department of Obstetrics and Gynecology,
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationEffect of baseline ovarian cysts on in vitro fertilization and gamete intrafallopian transfer cycles*
FERTILITY AND STERILITY Copyright 1991 The American Fertility Society Printed on acid-free paper in U.S.A. Effect of baseline ovarian cysts on in vitro fertilization and gamete intrafallopian transfer
More informationAssisted reproductive technology
Assisted reproductive technology FERTILITY AND STERILITY Vol. 60, No.2, August 1993 Copyright 'c; 199:~ The American Fertility Society Printed on acid-free paper in U. S. A. Natural cycle in vitro fertilization-embryo
More informationJinan Bekir, M.D. Amma Kyei-Mensah, M.D. Seang-Lin Tan, M.D.
FERTILITY AND STERILITY Copyright ~ 1995 American Society for Reproductive Mediciue Vol. 64, No.4, October 1995 Printed on acid-free paper in U. S. A. Administration of progestogens to hasten pituitary
More informationBulent Urman, M.D.* Margo R. Fluker, M.D. Basil Ho Yuen, M.B., Ch.B.t
FERTILITY AND STERILITY Copyright c 1992 The American Fertility Society Vol. 57, No.6, June 1992 Printed on acid-free paper in U.S.A. The outcome of in vitro fertilization and embryo transfer in women
More informationTimur Giirgan, M.D.* Bulent Urman, M.D. Hakan Yarali, M.D. Hakan E. Duran, M.D.
FERTILITY AND STEFULI~ Vol. 68, No. 3, September 1997 Copyright 1997 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Published by Elsevier Science Inc. Follicle-stimulating
More informationin vitro fertilization
FERTILITY AND STERILITY VOL 69, NO. 6, JUNE 1998 Copyright (#1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Elevated levels of basal
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationGonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome
FERTILITY AND STERILITY Copyright e 1993 The American Fertility Society Vol. 59, No.3, March 1993 Printed on acid-free paper in U.S.A. Gonadotropin-releasing hormone agonist reduces the miscarriage rate
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationA Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist
1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationUse of buserelin acetate in an in vitro fertilization program: a comparison with classical clomiphene citrate-human menopausal gonadotropin treatment
FERTILITY AND STERILITY Copyright'" 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Use of buserelin acetate in an in vitro fertilization program: a comparison with classical clomiphene
More informationPituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.
UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.
More informationPerformance of patients with a ''frozen pelvis" in an in vitro fertilization program
FERTILITY AND STERILITY Copyright 1987 The American Fertility Society Printed in U.8A. Performance of patients with a ''frozen pelvis" in an in vitro fertilization program David Molloy, F.R.A.C.O.G.*t
More informationConception rate after in vitro fertilization in patients who conceived in a previous cycle
FERTILITY AND STERILITY Copyright
More informationPituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.
UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationArticle Effect of cetrorelix dose on premature LH surge during ovarian stimulation
RBMOnline - Vol 16. No 6. 2008 772-777 Reproductive BioMedicine Online; www.rbmonline.com/article/3181 on web 18 April 2008 Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationIn vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome
Assisted reproductive techno.logy FERTILITY AND STERILITY Vol. 60, No.5, November 1993 Copyright 199a The American Fertility Society Printed on acid-free paper in U. S. A. In vitro fertilization and embryo
More informationA prospective randomized study comparing aspiration only with aspiration and flushing for transvaginal ultrasound-directed oocyte recovery
FERTILITY AND STERILITY Vol. 58, No.2, August 1992 Copyright e 1992 The American Fertility Society Printed on acid-free paper in U.S.A. A prospective randomized study comparing aspiration only with aspiration
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationAmir Ravhon, M.D., Ramon Aurell, M.D., Henrietta Lawrie, M.B., B.S., Raul Margara, M.D., and Robert M. L. Winston, F.R.C.O.G.
FERTILITY AND STERILITY VOL. 73, NO. 2, FEBRUARY 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. The significance
More informationComparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization
Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Peter Kovacs, M.D., a Timea Kovats, M.D., a Artur Bernard,
More informationEHY Ng, WSB Yeung, PC Ho. Introduction
Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study EHY Ng, WSB Yeung, PC Ho
More informationVery high serum estradiol levels are not detrimental to clinical outcome of in vitro fertilization
FERTILITY AND STERILITY Copyright 990 The American Fertility Society Printed on acid-free paper in U.S.A. Very high serum estradiol levels are not detrimental to clinical outcome of in vitro fertilization
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationHerjan Coelingh Bennink, M.D.:j: Andre Van Steirteghem, M.D., Ph.D.* Paul Devroey, M.D., Ph.D.*
J FERTILITY AND STERILITY@ Copyright 't; 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing
More informationArticle Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment
RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,
More informationK.W.Fuh, X.Wang, A.Tai, I.Wong and R.J.Norman 1
Human Reproduction vol.12 no.10 pp.2162 2166, 1997 Intrauterine insemination: effect of the temporal relationship between the luteinizing hormone surge, human chorionic gonadotrophin administration and
More informationIranian Journal of Reproductive Medicine Vol. 2. No.1 pp 29-33, 2004
Efficacy of Low Dose, Long-acting Gonadotropin Releasing Hormone Analogues (GnRH-a) Compared with Daily Injections of Short-acting GnRH-a in ART Cycles Robabeh Taheripanah M.D. 1, Mohammad A. Karimzadeh
More informationLiyan Duan 1, Shihua Bao 1, Kunming Li 1, Xiaoming Teng 1, Ling Hong 1 and Xiaoyu Zhao 2. Abstract. Introduction
doi:10.1111/jog.13305 J. Obstet. Gynaecol. Res. Vol. 43, No. 6: 1037 1042, June 2017 Comparing the long-acting and short-acting forms of gonadotropin-releasing hormone agonists in the long protocol of
More informationF.Zayed 1 ' 3, E.A.Lenton 1 ' 2 and I.D.Cooke 2
Human Reproduction vol.12 no. 11 pp.2408-2413, 1997 Comparison between stimulated in-vitro fertilization and stimulated intrauterine insemination for the treatment of unexplained and mild male factor infertility
More informationINTRODUCTION. Kang Woo Cheon, Sang Jin Song, Bum Chae Choi, Seung Chul Lee*, Hong Bok Lee*, Seung Youn Yu*, and Keun Jai Yoo
J Korean Med Sci 2008; 23: 662-6 ISSN 1011-8934 DOI: 10.3346/jkms.2008.23.4.662 Copyright The Korean Academy of Medical Sciences Comparison of Clinical Efficacy between a Single Administration of Long-Acting
More informationPatterns of serum-luteinizing hormone surges in stimulated cycles in relation to injections of human chorionic gonadotropin*
FERTILITY AND STERILITY Copyright ov 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Patterns of serum-luteinizing hormone surges in stimulated cycles in relation to injections
More informationThe outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology
Human Reproduction vol.14 no.1 pp.167 171, 1999 The outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology Lawrence Engmann 1,2,5, Noreen Maconochie
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Infertility Injectables Table of Contents Coverage Policy... 1 General Background...16 Coding/Billing Information...20 References...20 Effective Date...
More informationThe long-acting gonadotropin-releasing hormone analogues impaired the implantation rate*
FERTILITY AND STERILITY Copyright c 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. The long-acting gonadotropin-releasing hormone analogues impaired the implantation
More informationA comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study
Human Reproduction vol.14 no.2 pp.288 293, 1999 A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study T.Dada 1, O.Salha,
More informationGraham Burford, Ph.D. Albert Bernard, B.Sc. Bernard Bentick, M.R.C.O.G. Robert W. Shaw, M.D.t Claire A. Iflland, M.B.
FERTILITY AND STERILITY Copyright 1988 The American Fertility Society Printed in U.S.A. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after
More informationIVF Protocols: Hyper & Hypo-Responders, Implantation
IVF Protocols: Hyper & Hypo-Responders, Implantation Midwest Reproductive Symposium June 4-5, 4 2010 Subset : Hyper-Responders Mark R. Bush, MD, FACOG, FACS OBJECTIVE: Important goals for the PCOS patient
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationEffects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment
FERTILITY AND STERILITY VOL. 74, NO. 5, NOVEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effects of functional
More informationAssisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi
Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150
More informationThe influence of body mass index, basal FSH and age on the response to gonadotrophin stimulation in non-polycystic ovarian syndrome patients
Human Reproduction Vol.17, No.5 pp. 1207 1211, 2002 The influence of body mass index, basal FSH and age on the response to gonadotrophin stimulation in non-polycystic ovarian syndrome patients Sheila Loh
More informationUse of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF?
Human Reproduction Vol.17, No.8 pp. 2022 2026, 2002 Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF? J.B.Engel, M.Ludwig 1, R.Felberbaum,
More informationthat induce morphologic (4, 5) and biochemical (6) endometrial alterations relevant to uterine receptivity.
FERTILITY AND STERILITY VOL. 70, NO. 2, AUGUST 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. 12 Increasing uterine
More informationDifferent implantation rates after transfers of cryopreserved embryos originating from donated oocytes or from regular in vitro fertilization*
FERTILITY AND STERILITY Vol. 54, No. 4, October 1990 Copyright co 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Different implantation rates after transfers of cryopreserved
More informationInfertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary
Subfertility Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Infertility affects about 15 % of couples. age of the female. Other factors that
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationFactors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park
More information(1.,, ) (2.,,, )
33 11 Vol.33 No.11 2013 11 Nov. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.11.0749 E-mail: randc_journal@163.com IVF-ET 1 2 1 1 1 1 1 (1. 510150) (2. 510150) : (COH) (premature
More informationPrognostic value of day 3 estradiol on in vitro fertilization outcome*
FERTILITY AND STERILITY Vol. 64, No.6, December 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Prognostic value of day 3 estradiol on in vitro fertilization
More informationLars G.Westergaard 1, Karin Erb, Steen Laursen, Per E.Rasmussen and Sven Rex
Human Reproduction vol.11 no.6 pp. 1209-1213, 19% The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertuization in
More informationClinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationArticle Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
More informationIvf day 6 estradiol level
Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3
More informationDifferent follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation
Human Reproduction vol.8 no.9 pp. 1387-1391, 1993 Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation LJ.M.Duijkers 1 ' 4, H.M.Vemer 1, J.M.G.HoUanders 1, W.N.P.Willemsen
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Injectable Fertility Medications: Bravelle, Cetrotide, Follistim AQ, Ganirelix, Gonal-F, human chorionic gonadotropin, leuprolide, Menopur, Novarel, Ovidrel, Pregnyl,
More informationMinimal stimulation achieves pregnancy rates comparable to human menopausal gonadotropins in the treatment of infertility*
FERTILITY AND STERILITY Copyright :Q' 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Minimal stimulation achieves pregnancy rates comparable to human menopausal
More informationIVF Performance of Women Who Have Fluctuating Early Follicular FSH Levels 1
CLINICAL ASSISTED REPRODUCTION IVF Performance of Women Who Have Fluctuating Early Follicular FSH Levels 1 A. LASS, 2,3 A. GERRARD, 2 N. ABUSHEIKHA, 2 F. AKAGBOSU, 2 and P. BRINSDEN 2 Submitted: April
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 8/15/18 Pharmacy- Formulary 1 x Next Review: 6/18 Pharmacy- Formulary 2 x Date of Origin: 7/00 Injectable Fertility Medications: Bravelle,
More informationUtility of in vitro fertilization at diagnostic laparoscopy*
FERTILITY AND STERILITY Copyright" 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Utility of in vitro fertilization at diagnostic laparoscopy* Paul R. Gindoff, M.D.t Jerry L.
More informationArticle Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination
RBMOnline - Vol 13. No 2. 2006 208-212 Reproductive BioMedicine Online; www.rbmonline.com/article/2334 on web 30 May 2006 Article Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationDepartment of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. The effect of baseline complex ovarian cysts on in vitro fertilization outcome*t Elizabeth A.
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationInfertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations
Infertility Review and Update Clifford C. Hayslip MD Intrauterine Inseminations Beneficial effects of IUI not consistently documented in studies No deleterious effects on fertility 3-4 cycles of IUI should
More informationVanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More information' ' ' ' ' ' ' ' COMPARISON BETWEEN HIGHLY PURIFIED--FSH AND HMG FOR SUPEROVULATION IN WOMEN UNDERGOING IN VITRO FERTILIZATION ORIGINAL RESEARCH
' ' ' ' ORIGINAL RESEARCH ' ' ' ' COMPARISON BETWEEN HIGHLY PURIFIED--FSH AND HMG FOR SUPEROVULATION IN WOMEN UNDERGOING IN VITRO FERTILIZATION Pierre Miron, MD, FRCSC, 1 Robert Casper, MD, FRCSC,2 Louise
More informationOriginal Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer
Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and
More informationDouble-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology*
FERTILITY AND STERILITY Vol. 65, No.4, April 1996 Copyright 1996 American Society for Reproductive Medicine Printed on acid~free paper in U. S. A Double-blind placebo controlled study: human biosynthetic
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationAlternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment
Human Reproduction Vol., No.11 pp. 319 3197, 5 Advance Access publication July 1, 5. doi:.93/humrep/dei Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationProspective randomized study on the cryopreservation of human embryos with dimethylsulfoxide or 1,2-propanediol protocols*t
FERTILITY AND STERILITY Vol. 63, No. I, January 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Prospective randomized study on the cryopreservation
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24875
More informationNew York Science Journal 2014;7(4)
The Minimal Stimulation Protocol for ICSI: An Alternative Protocol for Ovarian Stimulation Adel Elsayed Ibrahim, MD Assisted Reproductive Unit Azhar University Adel.sayed29@gmail.com Abstract: Background:
More informationStimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization
FERTILITY AND STERILITY Copyright" 1991 The American Fertility Society Vol. 55, No.2, February 1991 Printed on acid-free paper in U.S.A. Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationAssisted Reproduction. Rajeevi Madankumar, 1,2 James Tsang, 1 Martin L. Lesser, 1 Daniel Kenigsberg, 1 and Steven Brenner 1 INTRODUCTION
( C 2005) DOI: 10.1007/s10815-005-4912-8 Assisted Reproduction Clomiphene citrate induced ovulation and intrauterine insemination: effect of timing of human chorionic gonadotropin injection in relation
More informationAssociation of estradiol levels on the day of hcg administration and pregnancy achievement in IVF: a systematic review
Human Reproduction Vol.19, No.11 pp. 2446 2453, 2004 Advance Access publication October 7, 2004 doi:10.1093/humrep/deh473 Association of estradiol levels on the day of hcg administration and pregnancy
More informationSonographic determination of a possible adverse effect of domiphene citrate on endometrial growth
Human Reproduction vol.5 no.6 pp.670-674, 1990 Sonographic determination of a possible adverse effect of domiphene citrate on endometrial growth Yael Gonen 1 and Robert F.Casper Division of Reproductive
More information